The company has several juicy growth opportunities ahead of it, a market professional tracking its fortunes believes.

Vertex has the revenue power to excel during any market environment.

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Financial giants have made a conspicuous bullish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:VRTX) revealed 35 unusual trades. Delving into the ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.

Vertex Pharmaceuticals' shares dropped due to poor first-quarter results. The company tends to run up after significant price drops. Vertex's business and prospects remain attractive. However, ...

Vertex Pharmaceuticals Incorporated faces slowing Trikafta/Kaftrio sales and a stock-price divergence with peers. Click for this VRTX earnings update.

Learn more about whether Hut 8 Corp. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. VERX offers steady low-teens growth, expanding margins, and a sticky tax compliance software ...